Yan Niu | Pharmaceutical Chemistry | Research Excellence Award

Published on by Top Pharmaceutical

Prof. Yan Niu | Pharmaceutical Chemistry | Research Excellence Award

Peking University | China

Prof. Yan Niu has established a solid and credible scholarly footprint within the global pharmaceutical sciences community, as demonstrated by his citation performance and publication metrics. His research portfolio comprises 46 peer-reviewed scientific documents, published in reputable international journals indexed in major databases such as Scopus and SCI. These publications collectively have attracted 538 citations, reflecting sustained academic attention and continued relevance of his work. Importantly, these citations originate from 447 independent citing documents, indicating that his research has been widely referenced across diverse studies rather than concentrated within a narrow citation network.An h-index of 14 further illustrates the balance between productivity and impact in Prof. Niu’s academic career. This metric signifies that at least fourteen of his publications have each received a minimum of fourteen citations, underscoring consistent influence across multiple research outputs rather than reliance on a small number of highly cited papers. Such a profile is characteristic of researchers whose work contributes foundational knowledge and methodological innovation to their field.The citation impact of Prof. Niu’s publications is closely aligned with the scientific significance of his research areas, particularly targeted protein degradation, amino acid-based hydrophobic tagging strategies, and the discovery and optimization of biologically active small molecules. These topics are at the forefront of modern drug discovery, attracting interdisciplinary interest from medicinal chemists, pharmacologists, and translational researchers. Collectively, his citation metrics not only quantify academic recognition but also reflect the practical and conceptual value of his contributions to advancing innovative therapeutic strategies and expanding the chemical biology toolkit available to pharmaceutical research.

Citation Metrics (Scopus)

600

450

300

150

0

Citations
538

Documents
46

h-index
14


View Scopus Profile

Featured Publications

Amirhosein Kefayat | Pharmaceutical Chemistry | Top Pharmaceutical Scientist Award

Published on by Top Pharmaceutical

Dr. Amirhosein Kefayat | Pharmaceutical Chemistry | Top Pharmaceutical Scientist Award

Edinburgh of University | United Kingdom

Dr. Amirhosein Kefayat is a distinguished physician-scientist specializing in oncology, nanomedicine, cancer immunotherapy, and radiation oncology, with extensive experience in translational research and clinical studies. He earned his Doctorate of Medicine (MD) from Isfahan University of Medical Sciences in 2019 and has since advanced his qualifications with multiple prestigious certifications, including full registration with the General Medical Council (UK) and ongoing ECFMG certification for the United States.Currently serving as a Clinical Research Fellow at the Institute of Genetics & Cancer, University of Edinburgh & NHS Lothian (UK), Dr. Kefayat contributes to UK-wide clinical trials such as ACESO, BIOPIC, DEFINE, PROFILE, PAN-IBD, and Gut Cell Atlas. He also leads systematic review and meta-analysis teams, influencing major clinical guidelines like the British Society of Gastroenterology 2024 update.Previously, as a Clinical Research Fellow at the Dept. of Radiotherapy & Oncology, Arak University of Medical Sciences (Iran), he led multiple high-impact research projects, resulting in numerous publications, international conference presentations, patents, and national research grants (INSF, NIMAD).Dr. Kefayat has published extensively in top Q1 journals such as Carbohydrate Polymers, Biosensors & Bioelectronics, Vaccine, Scientific Reports, Journal of Biomolecular Structure & Dynamics, and Nanomedicine. His work on novel cancer vaccines, wound healing biomaterials, and radiosensitizers ranks among the top 1–10% most-cited papers worldwide, reflecting his global research impact.His notable accolades include recognition as the top 0.5% of scholars worldwide (2024), membership in Iran’s National Elites Foundation, and multiple national research grants. His patented biomaterial for diabetic wound healing demonstrates his commitment to bridging laboratory research with clinical application.

Profile: Google Scholar

Featured Publications

Eskandarinia, A., Kefayat, A., Agheb, M., Rafienia, M., & Amini Baghbadorani, M. (2020). A novel bilayer wound dressing composed of a dense polyurethane/propolis membrane and a biodegradable polycaprolactone/gelatin nanofibrous scaffold. Scientific Reports, 10(1), 3063.

Eskandarinia, A., Kefayat, A., Gharakhloo, M., Agheb, M., Khodabakhshi, D., Rafienia, M., & Navid, S. (2020). A propolis enriched polyurethane-hyaluronic acid nanofibrous wound dressing with remarkable antibacterial and wound healing activities. International Journal of Biological Macromolecules, 149, 467–476.

Safavi, A., Kefayat, A., Mahdevar, E., Abiri, A., & Ghahremani, F. (2020). Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches. Vaccine, 38(48), 7612–7628.

Khodabakhshi, D., Eskandarinia, A., Kefayat, A., Rafienia, M., Navid, S., & Agheb, M. (2019). In vitro and in vivo performance of a propolis-coated polyurethane wound dressing with high porosity and antibacterial efficacy. Colloids and Surfaces B: Biointerfaces, 178, 177–184.

Eskandarinia, A., Kefayat, A., Rafienia, M., Agheb, M., Navid, S., & Ebrahimpour, K. (2019). Cornstarch-based wound dressing incorporated with hyaluronic acid and propolis: In vitro and in vivo studies. Carbohydrate Polymers, 216, 25–35.

Karizmeh, M. S., Poursamar, S. A., Kefayat, A., Farahbakhsh, Z., & Rafienia, M. (2022). An in vitro and in vivo study of PCL/chitosan electrospun mat on polyurethane/propolis foam as a bilayer wound dressing. Biomaterials Advances, 135, 112667.

Ghahremani, F., Shahbazi-Gahrouei, D., Kefayat, A., Motaghi, H., & Amouheidari, A. (2018). AS1411 aptamer conjugated gold nanoclusters as a targeted radiosensitizer for megavoltage radiation therapy of 4T1 breast cancer cells. RSC Advances, 8(8), 4249–4258.

Safavi, A., Kefayat, A., Abiri, A., Mahdevar, E., Behnia, A. H., & Ghahremani, F. (2019). In silico analysis of transmembrane protein 31 (TMEM31) antigen to design novel multiepitope peptide and DNA cancer vaccines against melanoma. Molecular Immunology, 112, 93–102.